Akcea, Ionis win over most FDA experts to their rare disease drug volanesorsen, vastly improving odds of success
Akcea Therapeutics $AKCA faced a tough uphill battle in search of an approval for their rare disease drug volanesorsen today — and they won.
The FDA advisory committee vote on the drug — spun out from Ionis $IONS — was 12 for, 8 against. The FDA, of course, doesn’t have to go along. But for a rare disease, they usually do — particularly under this administration.
Akcea’s shares shot up 20% in pre-market trading on Friday, starting the day with a $1.8 billion market cap, while Ionis saw a spike of 5%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
